Settling the uncertainty about unconventional circulating tumor cells: Epithelial-to-mesenchymal transition, cell fusion and trogocytosis

• DOI: 10.1016/bs.ircmb.2023.07.004
• Publication Date: 2023-08-08T07:00:53Z
• Authors: Giulia Gallerani; Tania Rossi; Manuela Ferracin; Massimiliano Bonafè
• Keywords: Cell Fusion; Epithelial-Mesenchymal Transition; Atypical CTC; Cell-fusion; Circulating tumor cells; Dual positive CTC; Epithelial-mesenchymal transition; Hybrid cells; Trogocytosis; Uncertainty; Humans; Neoplastic Cells, Circulating; Trogocytosis

Circulating tumor cells (CTCs) were first described 150 years ago. The so-called "classical" CTC populations (EpCAM+/CK+/CD45-) have been fully characterized and proposed as the most representative CTC subset, with clinical relevance. Nonetheless, other "atypical" or "unconventional" CTCs have also been identified, and their critical role in metastasis formation was demonstrated. In this chapter we illustrate the studies that led to the discovery of unconventional CTCs, defined as CTCs that display both epithelial and mesenchymal markers, or both cancer and immune markers, also in the form of hybrid cancer-immune cells. We also present biological explanations for the origin of these unconventional CTCs: epithelial to mesenchymal transition, cell-cell fusion and trogocytosis. We believe that a deeper knowledge on the biology of CTCs is needed to fully elucidate their role in cancer progression and their use as cancer biomarkers.